Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Delivra (Pharmaceuticals)

Delivra (Pharmaceuticals)?uq=kzBhZRuG
2007 FOUNDED
PUBLIC STATUS
11-20 EMPLOYEES
WKA.P STOCK SYMBOL
1 INVESTMENTS
Description

Developer of bio-medical skin cream created to shuttle pharmaceutical and natural molecules, through the skin, in a targeted specific manner. The company's cream is developed using a transdermal delivery system platform that helps in manufacturing and developing skin creams that relieves joint and muscle pain, nerve pain, varicose veins and wound healing, enabling pharmaceutical companies to treat a broad range of skin conditions leveraging technology.

Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
TSX
Primary Office
  • 347 Grays Road
  • Hamilton, Ontario L8E 2Z1
  • Canada

+1 (905) 000-0000

Delivra (Pharmaceuticals) Financials Summary

In Thousands,
USD
TTM
30-Jun-2015
FY 2015
30-Jun-2015
Revenue 1,366 1,366
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Delivra (Pharmaceuticals) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Delivra (Pharmaceuticals)‘s full profile, request access.

Request full access to PitchBook

Delivra (Pharmaceuticals) Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000000 000000 21-Dec-2015 000000000000000000 00.000 Other Financial Services 00000 00000000
To view this company’s complete investment and acquisition history, request access »

Delivra (Pharmaceuticals) Executive Team (5)

Name Title Board
Seat
Contact
Info
Joseph Gabriele Ph.D Founder, Chief Executive Officer, Chief Science Officer & Director
Chris Schnarr Chief Financial Officer and President
Howard Lichtman Chief Marketing Officer
Jeff Hull Director

1 Former Executive

You’re viewing 4 of 5 executives. Get the full list »